If you have been in mental health treatment for any length of time, you have probably started hearing the phrase interventional psychiatry without anyone stopping to explain it. It sounds technical, and a little intimidating. It is neither.

Here is the plain version. Most psychiatric care has historically worked through two channels: talking and swallowing. Psychotherapy changes how you understand and respond to your own experience. Medication changes brain chemistry through a pill taken daily, working gradually and throughout the whole body. Both help a great many people, and both remain the foundation of good care. Neither helps everyone.

Interventional psychiatry is a third channel. It describes treatments that act on the brain more directly, through magnetic fields, through rapid-acting medications given in a monitored clinical setting, through procedures rather than daily prescriptions. The defining feature is not that these treatments are stronger or more serious. It is that they take a different route to get where they are going. The Vikings did not find new coastlines by rowing the same fjord harder. At some point you stop adjusting the oars and try a different sea.

Who it is actually for

The honest answer is: not everyone, and not first.

If you have never tried an antidepressant, interventional treatment is almost certainly not your starting point. If therapy has been helping and you want more of it, keep going. These treatments exist for a narrower situation, and it is a common one: you have done the work, you have tried the reasonable things, and you are still unwell.

In clinical language this is often called treatment-resistant depression, which I have never loved as a phrase. It puts the resistance in the patient. What it actually describes is a depression that has not responded adequately to two or more medication trials at reasonable doses for reasonable durations. That is a description of what the illness has done, not a verdict on how hard someone has tried.

People who arrive at this point are usually exhausted in a particular way. They have been told to be patient through six-week medication trials, more than once. They have collected side effects. Some of them have started to believe the problem is that they are unfixable. Interventional options matter partly because they offer a genuinely different mechanism, and partly because a different mechanism means the previous failures were never a verdict.

What is actually in the category

Transcranial magnetic stimulation. TMS uses focused magnetic pulses to stimulate specific brain regions involved in mood regulation. You sit in a chair, awake, and go about your day afterward. No anesthesia, no sedation, no recovery time. No, it will not erase your credit cards. Yes, I get asked. Deep TMS is a variation that uses a differently shaped coil to reach broader and deeper cortical regions. TMS is FDA-cleared for major depressive disorder, and specific systems carry additional clearances including obsessive-compulsive disorder. Treatment runs daily on weekdays over several weeks, which is a real scheduling commitment and worth planning around honestly. A newer accelerated protocol, which you may hear called SAINT or SNT, compresses the course into about five days of imaging-guided sessions; it earned FDA clearance in 2022 and is steadily expanding in clinical use.

Esketamine (Spravato®). A nasal spray, FDA-approved for treatment-resistant depression and for depressive symptoms in adults with major depressive disorder and acute suicidal ideation or behavior. It is administered in a certified healthcare setting under a REMS safety program, with monitoring for two hours afterward. That monitoring requirement is not bureaucratic caution; it reflects genuine effects on blood pressure and dissociation that need a clinician in the room.

Ketamine. Given intravenously or intramuscularly, ketamine has substantial research support in depression but is used off-label for that purpose in the United States. Ketamine-assisted psychotherapy pairs the medication session with structured therapeutic work rather than treating the infusion as the entire intervention. I think the distinction matters. The medication opens a window; what happens in that window is not automatic.

Electroconvulsive therapy (ECT). Most of what people know about ECT comes from a movie made in 1975 about a hospital from the 1950s. Modern ECT is delivered under brief general anesthesia with careful monitoring, and it remains one of the most effective treatments in all of psychiatry, particularly for severe, psychotic, or life-threatening depression. Hollywood owes it an apology. The evidence here keeps moving: in the largest head-to-head trial, published in the New England Journal of Medicine, ketamine went toe-to-toe with ECT for nonpsychotic treatment-resistant depression and was noninferior, with a numerically higher response rate. A 2026 pooled analysis then found ECT tends to improve symptoms faster over a standard four-week course. Translation: two strong tools with different strengths, and the right one depends on the person in front of the clinician, not on which tool the clinic happens to own. We do not offer ECT at Viking; when it is the right tool, we say so and refer.

Vagus nerve stimulation (VNS). An implanted device, FDA-approved for chronic treatment-resistant depression, that delivers scheduled pulses to the vagus nerve. Think of it as a pacemaker for mood circuitry, with a longer runway: benefits build over months rather than weeks. It is generally reserved for depression that has resisted many treatments over years, and it is also a referral from our practice rather than an in-house service.

Nitrous oxide. An emerging option with promising early research in depression, used off-label. I would rather describe the evidence plainly than let enthusiasm outrun it, so here it is: the studies are small, the results are encouraging, and larger trials are underway. This is one we do offer at Viking, under our Noxout program, for adults and adolescents. Our clinical experience so far has been encouraging too, and encouraging is not the same as proven; we say that out loud in the treatment room as well.

Psychedelic-assisted treatments, labeled honestly. Psilocybin posted positive Phase 3 results in early 2026 and is on an accelerated regulatory path, with a possible FDA decision between late 2026 and early 2027. An LSD-based medication reported positive Phase 3 results for depression in June 2026. MDMA, on the other hand, was rejected by the FDA in 2024. None of these are approved or available outside clinical trials today. Investigational means investigational, and anyone offering you one outside a trial is not ahead of the science, they are outside it.

What I want you to take from this

Two things.

First, these are not last resorts in the way that phrase usually implies. They are simply different tools, and the sequencing that puts them late in the process has as much to do with insurance requirements and clinic availability as with medical necessity.

Second, none of them is a guarantee. Response rates in the research are meaningfully encouraging and they are not universal. Any clinician who promises you an outcome is telling you something they cannot know. What I can tell you is that running out of options within one mechanism was never the same as running out of options. The map is bigger than the corner of it you have been stuck in, and it keeps growing. That is not optimism as a personality trait; that is just what the field looks like right now.

If you have been circling this question for a while, it is worth an actual conversation with a clinician who can look at your full history, what you have tried, at what doses, for how long, and what happened. That conversation is more useful than any article, including this one.

Sean Goddard, MSN, APRN, PMHNP-C, AGPCNP-BC, is a dual board-certified nurse practitioner, certified in psychiatric-mental health and adult-gerontology primary care, and the founder of Viking Psychiatry & Wellness in Fort Wayne, Indiana. He is currently pursuing his Doctor of Nursing Practice (DNP). This article is general education and is not medical advice or a substitute for evaluation by your own clinician.

For transparency: Viking Psychiatry & Wellness provides Deep TMS as a BrainsWay center, Spravato® under its REMS program, ketamine therapy, ketamine-assisted psychotherapy, and nitrous oxide through the Noxout program. ECT and VNS are available by referral. Last reviewed July 2026.